Table 1.

Summary of antiemetic efficacy of pharmaceutical cannabinoids in patients with CINV

Treatments	Studies, n (no. of patients)	Statistical significance of treatments
		Resolution of nausea and vomiting, RR (95% CI)	Resolution of nausea, RR (95% CI)	Resolution of vomiting, RR (95% CI)
Dronabinol or nabilone vs prochlorperazine [25]	9 (n = 1221)	2.0 (0.7–5.4)	1.5 (0.7–3.2)	1.1 (0.9–1.4)
Dronabinol vs prochlorperazine [23]	5 (n = 325)	0.7 (0.5–1.0); P = 0.03; NNT = 3.4	NR	NR
Nabilone vs prochlorperazine, alizapride, or domperidone [23]	6 (n = 277)	0.9 (0.7–1.1); P = 0.2	NR	NR
Dronabinol or nabilone vs prochlorperazine or alizapride [24]	13 (n = 422)	NR	1.4 (1.2–1.6); NNT = 6.4	1.3 (1.1–1.5); NNT = 8.0

Data presented for oral cannabinoids approved in the US for the treatment of CINV (i.e., dronabinol and nabilone)

CI confidence interval, CINV chemotherapy-induced nausea and vomiting, NNT number needed to treat, NR not reported, RR relative risk